Localisation and digital media services provider Zoo Digital (LON: ZOO) is seeing signs of recovery in activity and has received initial orders from two major US studios. This pushed up the share price by 67.6% to 15.5p. Gillian Wilmot and Mickey Kalifa are stepping down from the board after many years, and Nathalie Schwarz will replace Gillian Wilmot as chair. Two new non-executive directors will be appointed. The share price
Shares in Strategic Minerals (LON: SML) jumped by two-thirds to 3.5p following the latest assay results from two holes at the Redmoor tungsten tine copper project in Cornwall. They confirm high grades of tungsten and tin within in the sheeted vein system. Further results are due.
Tungsten West (LON: TUN), which owns the Devon-based Hemerdon tungsten and tin mine, published an updated project value on the back of strong metals prices. The NPV7.5% has increased from $190m to $1.7bn. Management followed this up with a fundraising of £44.4m at 18p/share, including a fully subscribed retail offer of £3m. The cash will finance the feasibility study and pay back the bridge facility. It will help to accelerate the move towards production in the third quarter. Debt financing discussions are continuing with multiple lenders. The share price increased 46.1% to 29p.
Advanced coating provider Hardide (LON: HDD) continues to win new business and this has sparked an upgrade in the forecast for 2025-26. The latest order is from a North American energy company, and it is worth $1m. This should be delivered in the second half. Cavendish has upgraded its earnings forecast by one-quarter to 1.9p/share on a £1m increase in forecast revenues to £9m. That shows the operational gearing of the business. The share price gained 43.8% to 23p.
FALLERS
Trellus Health (LON: TRLS), which has developed a digital platform to manage chronic health conditions, says it has enough funding for most of the first quarter of 2026, having reduced cash burn to $400,000/month, and it is in talks for additional funding. Revenues were $545,000 in 2025. Last year, the agreement with Pfizer to license patient support educational content for inclusion in Pfizer’s IBD digital application was renewed and it could be expanded this year. Trellus Health has begun launching the programme to support recruitment and enrolment optimisation for an ongoing mid-stage immunology and inflammation clinical trial sponsored by Takeda. There has been trimming of some major shareholdings in the company, including by Icahn School of Medicine, which has reduced the stake from 25% to 22.3%. The share price slumped 42.1% to 0.56p.
Image Scan (LON: IGE) says a major defence contract that was going to use the company’s ThreatScan® portable X‑ray systems has been terminated. The was a 36-month programme that would have been a major contributor to 2026-27 and 2027-28 revenues. The termination reduces the order book from £4.67m to over £1m. The share price slipped 29.3% to 1.45p.
Berenberg has cut its share price target for Next 15 Group (LON: NFG) from 580p to 510p, but it retains the buy recommendation. The share price declined 19.8% to 281p.
Trading in Celsius Resources (LON: CLA) was suspended on the ASX because of concerns about the resignation of a past auditor not being in accordance with the government regulations. Trading on AIM continues. The share price fell 18.4% to 0.775p. Later in the week, the Philippines authorities approved the renewal of the exploration permit for the Botilao porphyry copper-gold prospect.